Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | Phase 4 | 101 | AmgenINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT04952766 | Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults(EREVA) | completed | Phase 4 | 196 | Centre Hospitalier Régional d'OrléansOTHER | 1 | Dec 23, 2025 |
| clinicaltrials |
| NCT05511428 | Home Based Daratumumab Administration for Patients With Multiple Myeloma | completed | Phase 4 | 20 | Thomas Jefferson UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05555329 | Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study(POMAlternative) | completed | Phase 4 | 12 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT03768960 | A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent | completed | Phase 4 | 150 | Johnson & Johnson Private LimitedINDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT04217967 | Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | completed | Phase 4 | 211 | Peking Union Medical College HospitalOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06425276 | Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation | completed | Phase 4 | 67 | CASI Pharmaceuticals (China) Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT00733538 | Stage I Multiple Myeloma Treatment(IFM-01-04) | completed | Phase 4 | 89 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02286830 | Prolonged Protection From Bone Disease in Multiple Myeloma(Magnolia) | completed | Phase 4 | 158 | Thomas LundOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03619252 | Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents | completed | Phase 4 | 36 | Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyOTHER_GOV | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00622505 | Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants(Z-MARK) | completed | Phase 4 | 121 | Novartis PharmaceuticalsINDUSTRY | 1 | May 26, 2021 | clinicaltrials |
| NCT01087008 | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse(AZABACHE) | completed | Phase 4 | 103 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01731886 | Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | completed | Phase 4 | 60 | Columbia UniversityOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02958969 | Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma | completed | Phase 4 | 50 | Gregory PiazzaOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00211211 | FREE Study - Fracture Reduction Evaluation | completed | Phase 4 | 300 | Medtronic Spine LLCINDUSTRY | 1 | Dec 8, 2017 | clinicaltrials |
| NCT00361140 | Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) | completed | Phase 4 | 72 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02268890 | A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma | completed | Phase 4 | 18 | Johnson & Johnson Taiwan LtdINDUSTRY | 1 | Jul 11, 2016 | clinicaltrials |
| NCT00352703 | PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation | completed | Phase 4 | 145 | Swedish Orphan BiovitrumINDUSTRY | 0 | Nov 3, 2014 | clinicaltrials |
| NCT00029224 | Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions | completed | Phase 4 | 500 | NovartisINDUSTRY | 1 | Feb 1, 2012 | clinicaltrials |
| NCT00652041 | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma(TaCyDexVMP7) | completed | Phase 4 | 40 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00104104 | A Multiple Myeloma Trial in Patients With Bone Metastases | completed | Phase 4 | 179 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 29, 2011 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
Data updated 22 days agoSource updated May 11, 2026source: clinicaltrials